• Overview
  • Eligibility
  • More info
  • Locations

Chemoprevention Trial of Acitretin Versus Placebo in Solid Organ Transplant Recipients With Multiple Prior Treated Skin Cancers (NCT00003611)

National Cancer Institute (NCI)
RATIONALE: Chemoprevention therapy is the use of certain drugs to try to prevent the development or recurrence of cancer. The use of acitretin may be an effective way to prevent the recurrence or further development of skin cancer. PURPOSE: Randomized clinical trial to study the effectiveness of acitretin in preventing skin cancers in patients with at least two previously treated skin cancers who have undergone organ transplantation.
  • Drug: acitretin
    • Other: placebo
      Ages eligible for Study
      18 Years and older
      Genders eligible for Study
      All
      Accepts Healthy Volunteers
      No
      OBJECTIVES:

      - Determine the chemopreventive efficacy of acitretin in immunosuppressed solid organ transplant recipients with a history of multiple previous basal cell carcinoma (BCC) or squamous cell carcinoma (SCC) skin cancer resections.

      - Evaluate human papillomavirus (HPV) as a possible etiologic cofactor in the development of cutaneous epidermal dysplasia/carcinoma from skin tissues of these patients.

      - Determine the effect of acitretin on potential surrogate endpoint biomarkers and HPV DNA in normal (sun protected), sun-exposed, and dysplastic and carcinoma (SCC/BCC) skin specimens.

      OUTLINE: This is a randomized study. Patients are stratified according to age (at least 18 to under 50 vs 50 to 59 vs 60 to 69 vs 70 and over), number of prior skin cancers in past 5 years (2 vs 3 vs at least 4), time since most recent skin cancer occurrence (less than 12 months vs at least 12 months), sunburn susceptibility (none vs moderate vs high), visible skin damage (mild vs moderate vs severe).

      Patients receive either oral acitretin or placebo daily for 2 years. Skin biopsies are obtained at 1 year from normal areas and from any areas with skin cancer for genetic studies.

      Patients are followed every 6 months.

      11 locations

      United States (11)
      • CCOP - Scottsdale Oncology Program
        Scottsdale, Arizona, United States, 85259-5404
      • Mayo Clinic
        Jacksonville, Florida, United States, 32224
      • CCOP - Illinois Oncology Research Association
        Peoria, Illinois, United States, 61602
      • CCOP - Carle Cancer Center
        Urbana, Illinois, United States, 61801
      • CCOP - Iowa Oncology Research Association
        Des Moines, Iowa, United States, 50309-1016
      • CCOP - Wichita
        Wichita, Kansas, United States, 67214-3882
      • Mayo Clinic Cancer Center
        Rochester, Minnesota, United States, 55905
      • CentraCare Health Plaza
        Saint Cloud, Minnesota, United States, 56303
      • Medcenter One Health System
        Bismarck, North Dakota, United States, 58501
      • Rapid City Regional Hospital
        Rapid City, South Dakota, United States, 57709
      • CCOP - Sioux Community Cancer Consortium
        Sioux Falls, South Dakota, United States, 57104
      Status:
      completed
      Type:
      Interventional
      Phase:
      -
      Start:
      30 April, 2000
      Updated:
      11 July, 2016
      Participants:
      129
      A girl giving information about available additional trials.

      FindMeCure helps you find, understand and join clinical trials from all over the world.

      There are more clinical trials for your condition!